StockUS listing USELOXNASDAQHealthcareCapital Destroyer

Eloxx Pharmaceuticals, Inc.(ELOX) Stock Analysis | Healthcare

USD --+0.00%
Reward31Low
Risk50Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 43.69M
Reward Ratingⓘ31 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ50 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ELOX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Eloxx Pharmaceuticals, Inc.?

, a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.

AI Brief Pro

The brief on Eloxx Pharmaceuticals, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Eloxx Pharmaceuticals, Inc.?

, a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 43.69M, and a P/E ratio of 5.6x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Low (31)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio5.6263
Beta-169204.95
Insider Activity
12M windowNo data
No insider activity data available for this ticker.